Corrigendum to 'Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression?' [Journal of Neuroimmunology, 233 (2011) 221-227]

The authors regret that one of the author names for this article was presented incorrectly in the printed version. ‘Olga R. Bocharova’ should have been ‘Olga A. Bocharova’. The correct presentation of the author names can be seen above and in the online version of this paper. The authors would like to apologise for any inconvenience caused

Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression

The aim was to ascertain any possible linkage between humoral immune responses to principal biomarkers (α-synuclein monomers, its toxic oligomers or fibrils, dopamine and S100B) and cellular immunity in Parkinson's disease development. There were elevated autoantibody titers to α-synuclein monomers, oligomers plus fibrils in 72%, 56%, and 17% of Parkinsonian patients respectively with a 5-year disease duration. Additionally, there were increased titers to dopamine and S100B (96% and 89%) in the 5-year patient group. All of these values subsided in 10-year sufferers. Furthermore, CD3+, CD4+, CD8+ T-lymphocyte and B-lymphocyte subsets declined in the patient cohort during Parkinsonism indicating disease associated reductions in these lymphocyte subsets